Clinical Research Directory
Browse clinical research sites, groups, and studies.
LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial
Sponsor: VA Office of Research and Development
Summary
The purpose of this research is to gather information on the safety and effectiveness of spironolactone and chlorthalidone for treatment of high blood pressure in patients with moderate to advanced CKD. Both drugs have been approved by the Food and Drug Administration (FDA) for the treatment of high blood pressure since 1960.
Official title: LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD (LODESTAR) Trial
Key Details
Gender
All
Age Range
18 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
160
Start Date
2026-10-01
Completion Date
2032-06-30
Last Updated
2026-06-12
Healthy Volunteers
No
Interventions
phase 2A Chlorthalidone
very low dose (VLD) x 6 weeks then low dose (LD) x 6 weeks
phase 2A Spironolactone
very low dose (VLD) x 6 weeks then low dose (LD) x 6 weeks
phase 2A Chlorthalidone + Spironolactone
very low dose (VLD) x 6 weeks then low dose (LD) x 6 weeks
phase 2B Chlorthalidone LD + Spironolactone LD
compare combination LD with SPL LD at 12 weeks
Locations (1)
Richard L. Roudebush VA Medical Center, Indianapolis, IN
Indianapolis, Indiana, United States